Prelude Capital Management, LLC Pro Qr Therapeutics N.V. Transaction History

Prelude Capital Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 14, 2019	SELL	$15.25 - $22.4 $255,483 - $375,267	-16,753 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$6.45 - $21.6 $195,899 - $656,035	-30,372 Reduced 64.45%	16,753 $324,000
Q2 2018 Aug 14, 2018	BUY	$2.95 - $7.45 $139,018 - $351,081	47,125 New	47,125 $344,000
Q4 2017 Feb 14, 2018	SELL	$2.8 - $4.8 $41,160 - $70,560	-14,700 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$4.35 - $6.45 $63,944 - $94,815	14,700	14,700 $71,000

45.1M

31.4K

24.7K

Ticker PRQR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,362,096
Market Cap $81.4M
Description
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.